Phase
Condition
Muscle Pain
Arthritis And Arthritic Pain
Treatment
Mushroom
Mushroom Extract
Placebo Administration
Clinical Study ID
Ages > 18 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age ≥ 18 years
History of breast cancer, estrogen receptor positive (ER+), Her 2 positive ornegative
Fatigue ≥ 4/10
Currently taking any aromatase inhibitor in the curative setting and planning to beon such for at least 8 weeks after registration. (Patients on concurrent ovariansuppression [such as with leuprolide acetate, goserelin] are allowed)
Prior treatment: last chemotherapy ≥ 90 days prior to randomization (if treated withchemotherapy)
On a stable dose of pain medications if pain medications are being regularly used. (i.e., no change in dosage in the past 30 days)
If on supplements, must be on stable dose with no plan to change; not on or planningany acupuncture or other specific supportive modalities for fatigue or AIarthralgias
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
White blood cell count (WBC) ≥ 3,000/mm^3 (obtained ≤ 30 days prior torandomization)
Hemoglobin ≥ 10 g/dL (obtained ≤ 30 days prior to randomization)
Platelet count ≥ 100,000/mm^3 (obtained ≤ 30 days prior to randomization)
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 30 days prior torandomization)
Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 1.2 x ULN (obtained ≤ 30 days prior to randomization)
Prothrombin time (PT)/activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN (obtained ≤ 30 days prior to randomization)
Negative pregnancy test done ≤ 7 days prior to registration, for persons ofchildbearing potential only
Provide written informed consent
Ability to complete questionnaires
Willing to return to enrolling institution during the active monitoring phase of thestudy
Exclusion
Exclusion Criteria:
Other known uncontrolled medical conditions causing fatigue such as untreatedthyroid disease, depression, fibromyalgia, chronic fatigue syndrome, infection,autoimmune disease, or active/untreated hepatitis
Allergy to mushrooms
On anticoagulation medication or aspirin or having a known bleeding disorder
On any specific medication for fatigue (e.g., methylphenidate)
Metastatic cancer diagnosis (history of nodal metastases is allowed)
Chronic steroid use, unless on physiologic replacement doses
Current use of any medical mushrooms
On medications for diabetes
History of symptomatic hypotension
Taking CYP3A4, CYP2D6 sensitive substrates which can be located at the followinglink:
https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-exampl es-drugs-interact-cyp-enzymes-and-transporter-systems
Drugs which exhibit either >20% inhibition or >20% induction of CYP2E1 in vivo, suchas: Acetaminophen, Dapsone, Enflurane, Halothane, Isoflurane, & Theophylline
Taking CDK4/6 inhibitors or olaparib
Any of the following because this study involves an agent that has unknowngenotoxic, mutagenic and teratogenic effects:
Pregnant persons
Nursing persons
Persons of childbearing potential who are unwilling to employ adequatecontraception
Study Design
Study Description
Connect with a study center
Mayo Clinic Health System in Albert Lea
Albert Lea, Minnesota 56007
United StatesSite Not Available
Mayo Clinic Health Systems-Mankato
Mankato, Minnesota 56001
United StatesSite Not Available
Mayo Clinic in Rochester
Rochester, Minnesota 55905
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.